No abstract available
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Combined Modality Therapy
-
Cytarabine / administration & dosage
-
Diagnosis, Differential
-
Disease Progression
-
Dose-Response Relationship, Drug
-
Female
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Idarubicin / administration & dosage
-
Janus Kinase 2 / antagonists & inhibitors
-
Janus Kinase 2 / genetics
-
Leukemia, Myeloid, Acute / etiology
-
Leukemia, Myeloid, Acute / therapy
-
Middle Aged
-
Nitriles
-
Pneumonia / diagnosis
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects*
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use
-
Pulmonary Embolism / diagnosis
-
Pyrazoles / administration & dosage
-
Pyrazoles / adverse effects*
-
Pyrazoles / pharmacology
-
Pyrazoles / therapeutic use
-
Pyrimidines
-
Remission Induction
-
Respiratory Distress Syndrome / chemically induced*
-
Respiratory Distress Syndrome / diagnosis
-
Respiratory Distress Syndrome / diagnostic imaging
-
Respiratory Distress Syndrome / therapy
-
Substance Withdrawal Syndrome / etiology*
-
Substance Withdrawal Syndrome / therapy
-
Thrombocythemia, Essential / drug therapy*
-
Thrombocythemia, Essential / genetics
-
Tomography, X-Ray Computed
Substances
-
Nitriles
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Pyrimidines
-
Cytarabine
-
ruxolitinib
-
JAK2 protein, human
-
Janus Kinase 2
-
Idarubicin